Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

Per Soelberg Sorensen; Christian Ross; Katja Maria Clemmesen; Klaus Bendtzen; Jette Lautrup Frederiksen; Kai Jensen; Ole Kristensen; Thor Petersen; Soren Rasmussen; Mads Ravnborg; Egon Stenager; Nils Koch-Henriksen; Danish Multiple Sclerosis Study Group

doi:10.1016/S0140-6736(03)14541-2

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

Per Soelberg Sorensen, Christian Ross, Katja Maria Clemmesen, Klaus Bendtzen, Jette Lautrup Frederiksen, Kai Jensen, Ole Kristensen, Thor Petersen, Soren Rasmussen, Mads Ravnborg, Egon Stenager, Nils Koch-Henriksen, Danish Multiple Sclerosis Study Group

323 Citationer (Scopus)

Abstract

Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.

Originalsprog	Engelsk
Tidsskrift	Lancet
Vol/bind	362
Udgave nummer	9391
Sider (fra-til)	1184-91
Antal sider	8
ISSN	0140-6736
DOI	https://doi.org/10.1016/S0140-6736(03)14541-2
Status	Udgivet - 11 okt. 2003

Adgang til dokumentet

10.1016/S0140-6736(03)14541-2

Citationsformater

Sorensen, P. S., Ross, C., Clemmesen, K. M., Bendtzen, K., Frederiksen, J. L., Jensen, K., Kristensen, O., Petersen, T., Rasmussen, S., Ravnborg, M., Stenager, E., Koch-Henriksen, N., & Danish Multiple Sclerosis Study Group (2003). Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet, 362(9391), 1184-91. https://doi.org/10.1016/S0140-6736(03)14541-2

Sorensen, PS, Ross, C, Clemmesen, KM, Bendtzen, K, Frederiksen, JL, Jensen, K, Kristensen, O, Petersen, T, Rasmussen, S, Ravnborg, M, Stenager, E, Koch-Henriksen, N & Danish Multiple Sclerosis Study Group 2003, 'Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis', Lancet, bind 362, nr. 9391, s. 1184-91. https://doi.org/10.1016/S0140-6736(03)14541-2

@article{dabcb64c240a4744b70e5a65c51c2ada,

title = "Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis",

abstract = "Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.",

author = "Sorensen, {Per Soelberg} and Christian Ross and Clemmesen, {Katja Maria} and Klaus Bendtzen and Frederiksen, {Jette Lautrup} and Kai Jensen and Ole Kristensen and Thor Petersen and Soren Rasmussen and Mads Ravnborg and Egon Stenager and Nils Koch-Henriksen and Clemmesen, {Katja Maria}",

year = "2003",

month = oct,

day = "11",

doi = "10.1016/S0140-6736(03)14541-2",

language = "English",

volume = "362",

pages = "1184--91",

journal = "Lancet",

issn = "0140-6736",

publisher = "TheLancet Publishing Group",

number = "9391",

}

TY - JOUR

T1 - Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

AU - Sorensen, Per Soelberg

AU - Ross, Christian

AU - Clemmesen, Katja Maria

AU - Bendtzen, Klaus

AU - Frederiksen, Jette Lautrup

AU - Jensen, Kai

AU - Kristensen, Ole

AU - Petersen, Thor

AU - Rasmussen, Soren

AU - Ravnborg, Mads

AU - Stenager, Egon

AU - Koch-Henriksen, Nils

AU - Danish Multiple Sclerosis Study Group

PY - 2003/10/11

Y1 - 2003/10/11

N2 - Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.

AB - Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.

U2 - 10.1016/S0140-6736(03)14541-2

DO - 10.1016/S0140-6736(03)14541-2

M3 - Journal article

SN - 0140-6736

VL - 362

SP - 1184

EP - 1191

JO - Lancet

JF - Lancet

IS - 9391

ER -

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater